Exscientia is pleased announces it has signed an agreement with a major Top 10 US pharmaceutical company to collaborate on the discovery of 'bi-specific' enzyme inhibitors to treat metabolic diseases. The agreement focuses on ex scientia’s delivery of novel bi-specific compounds that selectively inhibit two specific enzymes from two diverse diseases gene families, using its design technology. Bi-specifics are a new small molecule drug modality that aim to deliver superior clinical efficacy. With this collaboration ex scientia is responsible for designing and selecting the compounds, whereas the partner provides access to the partners world class capabilities in medicinal chemistry, assay profiling and X-ray structure determination. Financial terms were not disclosed.